Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Psychiatry/Psychology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Schizophrenia and Schizoaffective Disorders Clinical Trials

A listing of Schizophrenia and Schizoaffective Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (9) clinical trials

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

A Prospective, matched-control, Randomized (assignment of study drug by chance), open-label, flexible-dose, study in participants with recent-onset schizophrenia or schizophreniform disorder to compare disease progression and disease modification following treatment with PP long-acting injection (once-monthly followed by 3-month injections) or OAP (Any of the following 7 OAPs are permitted: aripiprazole, ...


A clinical research study for the treatment of Schizoaffective, Schizophrenia, Paranoia, Psychosis

Objectives Schizophrenia and related psychoses are chronic brain disorders whose prognosis is often poor and whose pathophysiology remains obscure. Neuroimaging technologies such as PET (positron emission tomography), fMRI (functional magnetic resonance imaging), DTI (diffusion tensor imaging) and MRSI (magnetic resonance spectroscopic imaging) offer opportunities to elucidate the pathophysiology by studying ...

Phase N/A

A clinical trial sponsored by National Institute of Mental Health (NIMH) for a research study for the treatment of Magnetic Resonance Imaging, Genoty[e, Cognitioin Disorder, Psychosis

This protocol is meant to provide a matrix for multiple, simultaneous brain imaging investigations using magnetic resonance imaging (MRI) at 3.0 Tesla (3T). We intend to study regional brain structure, physiology, and biochemistry in living human subjects, both healthy and ill. Based on multiple clinical, neuropathological, and functional neuroimaging studies, ...

Phase N/A

Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia

Estrogen is hypothesised to be protective for women against early onset of severe symptoms of schizophrenia (Hafner, 1991; Seeman, 1992). This 'estrogen hypothesis' was derived from epidemiological, clinical and animal studies. Following the results of such studies, the investigators conducted a study (Kulkarni et al 1996) in which a group ...


A Phase 3 clinical study for patients using ALKS 3831, Olanzapine

In the US adolescent subjects starting at age 16 will be enrolled. In the EU, subjects age 18 and older will be enrolled.


A clinical research study of BI 409306, Placebo for the treatment of Psychosis

To investigate the efficacy, safety and tolerability of BI 409306 once daily compared to placebo given for 52 weeks to subjects with attenuated psychosis syndrome.


The Staged Treatment in Early Psychosis Study

The study treatment sequence involves three stages, which are referred to as steps: Step 1- Support and Problem Solving (SPS) All trial participants receive SPS treatment in Step 1. Step 1 involves attending weekly-fortnightly SPS sessions over a six week period and the Week 4 and 6 visits will also ...


Cannabis Schizophrenia and Reward: Self-Medication and Agonist Treatment?

Substance use disorders are strikingly common in patients with schizophrenia and contribute to its morbidity and cost to society. We have proposed a neurobiological formulation suggesting that cannabis and other substance use in these patients may ameliorate a dysfunction in the brain reward circuit(thus serving a "self-medication" function), while also ...


Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

The specific aims include: Primary aim: Examine the efficacy of exenatide weekly injection in improving negative symptoms as measured by the Scale for the Assessment of Negative Symptoms (SANS) total score. Secondary aims: Examine the efficacy of exenatide in improving cognition as measured by the Measurement and Treatment Research to ...